ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年07月31日 14時41分
Source:
Eisai
エーザイ、2020年3月期配当予想の修正(増配)に関するお知らせ
東京, 2019年07月31日 - (JCN Newswire) - 当社は、2019年7月31日開催の取締役会において、2020年3月期第2四半期末(中間)配当の予想について、下記の通り、修正(増配)することを決議しましたので、お知らせします。
1. 配当予想の修正について
2020年3月期第2四半期末(中間)配当の予想の修正(増配)
年間配当金(円)
第2四半期末/期末/合計
前回予想(2019年5月13日公表)70円00銭/80円00銭/150円00銭
今回修正予想 80円00銭/80円00銭/160円00銭
当期実績 -/-/-
前期実績(2019年3月期)70円00銭/80円00銭/150円00銭
2. 修正の内容
当社は、主要なステークホルダーズである患者様と生活者の皆様、株主の皆様および社員の価値増大をはかるとともに良好な関係の発展・維持に努めています。
配当につきましては、長期的なバランスシートマネジメントに依拠した「最適資本構成に基づく最適配当政策」を志向しており、連結業績、DOE(親会社所有者帰属持分配当率)およびフリー・キャッシュ・フローを総合的に勘案し、「シグナリング効果」も考慮して、株主の皆様へ継続的・安定的な配当を実施します。配当のKPIとしては、連結純資産に対する配当の比率を示すDOEを採択しています。
今回、これらの配当方針、ならびに好調な業績に基づく強固なバランスシートを勘案し、前回発表(2019年5月13日)の2020年3月期第2四半期末(中間)配当金予想を10円増配の80円に修正します。2010年3月期以来となる増配により期末配当金予想80円と合わせ、年間配当金予想は160円(前回予想は150円)、2020年3月期通期業績予想に基づくDOEは7.1%となる見込みです。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2019/news201959.html
概要:エーザイ株式会社
詳細はwww.eisai.co.jpをご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
The Executive Centre Celebrates 25 Years in Japan: A Commitment to Long-Term Growth and Investment
Jan 29, 2026 20:01 JST
MAZDA CX-5 Achieves Five Million Units in Global Production and Sales
Jan 29, 2026 16:15 JST
Hitachi reinvents Ellipse Enterprise Asset Management (EAM) solution with Microsoft's AI-enabled technology to improve critical infrastructure resilience
Jan 29, 2026 10:14 JST
TANAKA Recognized as a "Tokyo Sports Promotion Company" for the 11th Consecutive Year
Jan 28, 2026 22:00 JST
NTT, DOCOMO, and NTT DATA to Exhibit at MWC Barcelona 2026
Jan 28, 2026 18:29 JST
MHI Thermal Systems Receives "Minister of Economy, Trade and Industry Award" and MHI's Aerospace Parts Factory Receives "Agency for Natural Resources and Energy Commissioner's Award" at 2025 Energy Conservation Grand Prize Awards
Jan 28, 2026 18:08 JST
Mitsubishi Power Completes GTCC Upgraded Reliability Package at VPI's Damhead Creek Power Station
Jan 28, 2026 17:58 JST
Fujitsu and Tokai National Higher Education and Research System develop space weather prediction capabilities technology leveraging AI
Jan 28, 2026 10:55 JST
NEC Develops High-Efficiency, Compact Power Amplifier Module for 5G Base Station Radio Units
Jan 28, 2026 10:05 JST
Shoucheng Holdings-Backed Robotics Firms Set to Appear at 2026 CMG New Year's Gala
Jan 28, 2026 09:35 JST
The 19th Asian Financial Forum concludes successfully
Jan 27, 2026 23:27 JST
NTT DOCOMO Develops a Solution to Streamline DOOH Advertiser Review Operations
Jan 27, 2026 10:25 JST
Fujitsu launches new platform enabling autonomous operation of generative AI optimized for in-house applications in a dedicated environment
Jan 26, 2026 13:30 JST
Mitsubishi Heavy Industries and Mitsubishi Electric Invest in Japan LEO Shachu, a Space Venture Established by Mitsui & Co.
Jan 26, 2026 13:24 JST
CaoCao Inc. Ushers in China's Fully Purpose-Built Robotaxi Era, Aims to Deploy 100,000 Robotaxis by 2030
Jan 26, 2026 11:51 JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Jan 26, 2026 11:37 JST
Fujitsu to support Mizuho Financial Group's human capital disclosure with a non-financial information collection and disclosure support service
Jan 26, 2026 10:45 JST
TOYOTA GAZOO Racing Announces GR Yaris Sebastien Ogier 9x World Champion Edition
Jan 23, 2026 19:26 JST
NEC Develops New 5G Base Station Radio Unit for Enhanced Communication Throughput, Compactness, and Energy Efficiency
Jan 23, 2026 15:00 JST
GlobalLogic and Elektrobit Strengthen Partnership to Accelerate Next-Generation Software-Defined Vehicles
Jan 23, 2026 14:12 JST
More Latest Release >>
Related Release
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
1/26/2026 11:37:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
1/21/2026 4:44:00 PM JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
1/13/2026 9:50:00 AM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
1/6/2026 10:43:00 AM JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
12/11/2025 7:41:00 PM JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
12/9/2025 6:51:00 PM JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
12/4/2025 6:36:00 PM JST
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
12/3/2025 6:19:00 PM JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
12/3/2025 12:01:00 AM JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
11/28/2025 11:00:00 PM JST
More Press release >>